Latigo Biotherapeutics LTGO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$6.41M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 59.5% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 0.22% to 1.42% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Charles Schwab Investment Management | Mutual Fund | 2026/Q3 | +110,534 | 0.2% |
| Westlake Village BioPartners | VC/PE Fund | 2026/Q3 | +13,199,669 | 19.9% |
| FMR | Mutual Fund | 2026/Q3 | +2,878,973 | 4.3% |
| abrdn plc | Mutual Fund | 2026/Q3 | +935,718 | 1.4% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +865,977 | 1.3% |
| Sanofi | Public Company | 2026/Q3 | +672,778 | 1.0% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +293,297 | 0.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +292,086 | 0.4% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +220,175 | 0.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +216,879 | 0.3% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +9,108 | 0.0% |
| Leonard Blavatnik | Individual/Insider | 2026/Q3 | +3,193,565 | 4.8% |
| FMR | Mutual Fund | 2026/Q3 | +1,018,728 | 1.5% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +67,364 | 0.1% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +1,074 | 0.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Aug 2026 | Sanofi | Derivative Exercise and Retained | +672,778 | – | 672,788 | |
| 9 Aug 2026 | 5AM Venture Management, LLC | Derivative Exercise and Retained | +7,325,962 | – | 7,325,962 | |
| 9 Aug 2026 | Foresite Capital Management, LLC | Open Market Acquisition | +140,000 | $18.00 | 9,181,328 | |
| 9 Aug 2026 | Foresite Capital Management, LLC | Derivative Exercise and Retained | +9,041,328 | – | 9,181,328 | |
| 9 Aug 2026 | Westlake Village BioPartners | Derivative Exercise and Retained | +12,695,305 | – | 13,199,669 | |
| 5 Aug 2026 | James Tananbaum | Independent Director | Initial Statement of Beneficial | +0 | – | 1,484,401 |
| 5 Aug 2026 | Sanofi | Initial Statement of Beneficial | +0 | – | 494,800 | |
| 5 Aug 2026 | Andrew Schwab | Initial Statement of Beneficial | +0 | – | 1,484,401 | |
| 5 Aug 2026 | Timothy Walbert | Independent Chairperson | Initial Statement of Beneficial | +0 | – | 329,819 |
| 5 Aug 2026 | Todd Smith | PresIdent, CEO & Director | Other Derivative Acquisition | +105,542 | $18.00 | 105,542 |
| 5 Aug 2026 | Nima Farzan | Officer | Initial Statement of Beneficial | +0 | – | 2,787,966 |
| 5 Aug 2026 | Sara Bonstein | Independent Director | Initial Statement of Beneficial | +0 | – | 105,542 |
| 5 Aug 2026 | Westlake Village BioPartners | Initial Statement of Beneficial | +0 | – | 679,620 | |
| 5 Aug 2026 | Neha Krishnamohan | Chief Business Officer & CFO | Initial Statement of Beneficial | +0 | – | 686,026 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 941,434 | 1.4% | 5.4 |
| 15 Oct 2026 | 785,880 | 1.2% | 2.5 |
| 30 Sep 2026 | 832,088 | 1.3% | 1.6 |
| 15 Sep 2026 | 449,962 | 0.7% | 2.1 |
| 31 Aug 2026 | 308,625 | 0.5% | 1.7 |
| 14 Aug 2026 | 134,468 | 0.2% | 1.0 |
No comments yet — be the first to weigh in on LTGO.
Sign in to join the discussion.